SUDO-550
Neurological & Immunological Conditions (e.g., Multiple Sclerosis)
Phase 1Active
Key Facts
Indication
Neurological & Immunological Conditions (e.g., Multiple Sclerosis)
Phase
Phase 1
Status
Active
Company
About Sudo Biosciences
Sudo Biosciences is a private, pre-revenue biotech advancing a pipeline of novel TYK2 inhibitors for immune-mediated and neurological diseases. The company's lead asset, SUDO-550, has reported positive Phase 1 results and represents a differentiated, brain-penetrant approach targeting conditions like multiple sclerosis. Backed by experienced leadership and investors, Sudo leverages a precision drug design strategy anchored in human genetics and translational biology to develop potentially transformative therapies.
View full company profile